TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24640801

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.06 mg/kg 1 minute before succinylcholine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.06 mg/kg 5 minutes before succinylcholine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline 5 ml as placebo 1 minute before succinylcholine
Number of subjects: 90
Study: 22732780

Group type: EXPERIMENTAL
Intervention: 3 g fosfomycin trometamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 60
Study: 20964826

Group type: EXPERIMENTAL
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) with adjuvant androgen deprivation therapy (ADT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) without adjuvant androgen deprivation therapy (ADT)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) with adjuvant ADT
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Biopsy results at 36 months following treatment
Number of subjects: 420
Study: 16855015

Group type: EXPERIMENTAL
Intervention: Education with husbands
Number of subjects: 442

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 442

Group type: COMPARATOR
Intervention: No education
Number of subjects: 442
Study: 16284985

Group type: COMPARATOR
Intervention: Four courses of standard-dose consolidation therapy without maintenance (Arm A)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Three courses of standard-dose consolidation with six courses of maintenance therapy (Arm B)
Number of subjects: 789
Study: 12170044

Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules with dexamethasone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine microcapsules without dexamethasone
Number of subjects: 12
Study: 10462658

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy alone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Endoscopic variceal band ligation plus low-dose endoscopic variceal sclerotherapy
Number of subjects: 69
Study: 8578731

Group type: EXPERIMENTAL
Intervention: Whole Blood Filtration (WBF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Filtration (CF)
Number of subjects: 40
Study: 1967516

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg vecuronium
Number of subjects: 40
Study: 347467

Group type: COMPARATOR
Intervention: 20 mg prodipin infusion (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continued therapy without prodipin (group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 20 mg prodipin infusion (group 3)
Number of subjects: 28
Study: 31676120

Group type: EXPERIMENTAL
Intervention: Controlled-Flux Electrolyzed Acidic Solution (CFEAS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 19
Study: 30196720

Group type: EXPERIMENTAL
Intervention: EHR‐PACE program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 28417897

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (800 mg magnesium oxide daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 102
Study: 26552185

Group type: EXPERIMENTAL
Intervention: Psoraleae Fructus (40 g x kg(‐1))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Psoraleae Fructus and Glycyrrhizae Radix et Rhizoma (40 + 20 g x kg(‐1))
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vehicle control group (distilled water)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Positive control (aristolochic acid A) group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Glycyrrhizae Radix et Rhizoma group
Number of subjects: 35
Study: 23406914

Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation (NIV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 200
Study: 21485075

Group type: EXPERIMENTAL
Intervention: Electrical plum-blossom needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical comprehensive therapy
Number of subjects: 60
Study: 18722583

Group type: COMPARATOR
Intervention: D1 surgery
Number of subjects: 3432

Group type: COMPARATOR
Intervention: D2 surgery
Number of subjects: 3432

Group type: COMPARATOR
Intervention: D3 surgery
Number of subjects: 3432
Study: 17547588

Group type: EXPERIMENTAL
Intervention: Sibutramine (5-15 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topiramate (25-600 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 46
Study: 15503549

Group type: EXPERIMENTAL
Intervention: Topical gel treatment for severe periodontitis
Number of subjects: 31
Study: 12086119

Group type: EXPERIMENTAL
Intervention: New site-specific measure of quality of life for breast problems
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Generic quality of life scale (SF-36)
Number of subjects: 1063
Study: 9468466

Group type: EXPERIMENTAL
Intervention: Individualized treatment with adjusted doses of methotrexate, teniposide, and cytarabine based on drug clearance rates.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional therapy with fixed doses of methotrexate, teniposide, and cytarabine based on body-surface area.
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Individualized treatment for B-lineage leukemia patients.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional therapy for T-lineage leukemia patients.
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Methotrexate in individualized treatment.
Number of subjects: 182
Study: 8542807

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) 2.4 g daily by mouth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (5-ASA and Control)
Number of subjects: 60
Study: 2193998

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 27

Group type: COMPARATOR
Intervention: standard broad spectrum antibiotic therapy
Number of subjects: 27
Study: 438787

Group type: EXPERIMENTAL
Intervention: LT (long term, unlimited length of stay, mean 179 days)
Number of subjects: 173

Group type: COMPARATOR
Intervention: ST (short term, 90‐day limit)
Number of subjects: 173
Study: 31697336

Group type: EXPERIMENTAL
Intervention: Continuous dosing (4g/24h after a loading dose of 1g)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intermittent dosing (1g every 6h)
Number of subjects: 59
Study: 31260707

Group type: EXPERIMENTAL
Intervention: Peer influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert influence for consumers low in insect-based disgust sensitivity
Number of subjects: 0
Study: 29972287

Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) intervention
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1156
Study: 26983031

Group type: EXPERIMENTAL
Intervention: ALF-5755
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 24834865

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 42
Study: 22182261

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE)
Number of subjects: 126
Study: 19156894

Group type: EXPERIMENTAL
Intervention: Intensive timing (phase 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (phase 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy, autologous SCT, and allogeneic SCT (phase 2)
Number of subjects: 0
Study: 17484870

Group type: EXPERIMENTAL
Intervention: Erythromycin (12.5 mg/kg/dose every 6 hours for 14 days)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 182
Study: 15110741

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 20
Study: 12397861

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 24
Study: 9565436

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements (100,000 IU for children ≤1 year and 200,000 IU for children >1 year on admission, followed by 50,000 IU and 100,000 IU respectively the next day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 7932681

Group type: EXPERIMENTAL
Intervention: Home-based intervention program (four nurse home visits during the first 6 months of life)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 121
Study: 3279698

Group type: EXPERIMENTAL
Intervention: BCG RIVM (1 x 10(9) bacilli in 50 mL saline) administered once a week for six consecutive weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Mitomycin C (30 mg in 50 mL saline) administered once a week for one month and thereafter once a month for a total of six months
Number of subjects: 308
Study: 28485200

Group type: EXPERIMENTAL
Intervention: Rapid cardiothoracic ultrasound (CaTUS) protocol combining lung ultrasound (LUS) and focused echocardiographic evaluation of cardiac filling pressures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rapid cardiothoracic ultrasound (CaTUS) protocol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LUS response
Number of subjects: 60
Study: 27659572

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheters
Number of subjects: 200

Group type: COMPARATOR
Intervention: Uncoated balloon catheters
Number of subjects: 200
Study: 25291749

Group type: EXPERIMENTAL
Intervention: Trifocal diffractive IOL AT LISA tri 839 MP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bifocal diffractive IOL AT LISA 801
Number of subjects: 30
Study: 24237191

Group type: EXPERIMENTAL
Intervention: Chamomile, meadowsweet, and willow bark (CMW) in a berry extract matrix
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (berry extract matrix)
Number of subjects: 20
Study: 20876922

Group type: EXPERIMENTAL
Intervention: Long-term TENS therapy via L-S orthoses (3 times a day for 20 minutes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional TENS therapy (once a day for 20 minutes)
Number of subjects: 39
Study: 18448861

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 384
Study: 17160228

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection using patent blue alone or in association with radiotracer based on technetium 99m colloid solution.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Addition of transoperative lympho‐scintigraphy.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection and analysis.
Number of subjects: 31
Study: 14981970

Group type: EXPERIMENTAL
Intervention: sME treatment (therapy group)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Control group (no complementary treatment)
Number of subjects: 689
Study: 10744093

Group type: EXPERIMENTAL
Intervention: Baseline comparability presented in tables
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Significance tests for baseline comparison
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methods of randomisation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Unadjusted results
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subgroup findings
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 50
Study: 8792735

Group type: EXPERIMENTAL
Intervention: PCA Modular femoral component (n=9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Modified version of the same prosthesis (n=9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Duracon femoral component (n=11)
Number of subjects: 29

Group type: COMPARATOR
Intervention: All femoral components (PCA Modular, modified version, Duracon)
Number of subjects: 29
Study: 8456467

Group type: EXPERIMENTAL
Intervention: Triple drug therapy (low-dose cyclosporine, azathioprine, methylprednisolone)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aza plus CsA
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Aza plus MP
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CsA plus MP
Number of subjects: 128
Study: 3079888

Group type: EXPERIMENTAL
Intervention: Parlodel, 2.5 mg daily for 1-3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29301646

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 8404
Study: 26966353

Group type: EXPERIMENTAL
Intervention: Optimized formulation of CTZ-loaded polymethacrylate microspheres (10 mg CTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial product of CTZ (marketed CTZ tablets)
Number of subjects: 0
Study: 25011515

Group type: EXPERIMENTAL
Intervention: Preoperative high-dose-rate intracavitary brachytherapy (2x8Gy)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Surgery alone (no preoperative treatment)
Number of subjects: 185
Study: 23232585

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified drink
Number of subjects: 246
Study: 21978349

Group type: EXPERIMENTAL
Intervention: Practitioner Asthma Communication and Education (PACE) Australia program
Number of subjects: 221
Study: 18068940

Group type: EXPERIMENTAL
Intervention: PregXercise CD‐ROM
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD‐ROM with neutral content
Number of subjects: 0
Study: 16688997

Group type: EXPERIMENTAL
Intervention: Ginaton (0.5 mg/kg) added to St. Thomas' cardioplegic perfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no Ginaton)
Number of subjects: 40
Study: 12967065

Group type: EXPERIMENTAL
Intervention: Colgate Simply‐White Whitening Gel (5.9% hydrogen peroxide)
Number of subjects: 22
Study: 10741708

Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electric pulses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 10
Study: 8936392

Group type: EXPERIMENTAL
Intervention: Left movers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Right movers
Number of subjects: 24
Study: 1303133

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 0
Study: 2412032

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d. given orally for 4 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 7
Study: 31376917

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 18F-FDG-PET
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ki-67 index
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Clinical signature and fusion signature
Number of subjects: 123
Study: 29337653

Group type: EXPERIMENTAL
Intervention: 4CMenB+Routine
Number of subjects: 225

Group type: COMPARATOR
Intervention: Routine
Number of subjects: 225
Study: 26910293

Group type: EXPERIMENTAL
Intervention: Self-exercise with a therapeutic inflatable ball (SEIB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound (US) therapy
Number of subjects: 40
Study: 23983091

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (3 times a week for 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting list control group (normal activity)
Number of subjects: 27
Study: 22568406

Group type: EXPERIMENTAL
Intervention: Instrumental vaginal delivery due to fetal distress
Number of subjects: 5667

Group type: EXPERIMENTAL
Intervention: Caesarean section due to fetal distress
Number of subjects: 5667

Group type: EXPERIMENTAL
Intervention: Instrumental vaginal delivery due to failure to progress
Number of subjects: 5667

Group type: EXPERIMENTAL
Intervention: Caesarean section due to failure to progress
Number of subjects: 5667
Study: 20533625

Group type: EXPERIMENTAL
Intervention: One-step All Bond SE protocol (SE-1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Two-step All Bond SE protocol (SE-2)
Number of subjects: 33
Study: 17611095

Group type: EXPERIMENTAL
Intervention: Grazax
Number of subjects: 14000000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 14000000
Study: 16163148

Group type: EXPERIMENTAL
Intervention: Rusch hygroscopic HME
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mediflux hygroscopic HME
Number of subjects: 20
Study: 11791082

Group type: EXPERIMENTAL
Intervention: E(2)/NETA (Activella)
Number of subjects: 438

Group type: COMPARATOR
Intervention: CEE/MPA (Prempro)
Number of subjects: 438
Study: 10506679

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7611241

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg) on low salt diet (50 mmol Na/d)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg) on high salt diet (200 mmol Na/d)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg) on moderate salt diet (100 mmol Na/d)
Number of subjects: 3
Study: 1609377

Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 6469428

Group type: EXPERIMENTAL
Intervention: Fixed combination of 50 mg atenolol and 12.5 mg chlorthalidone (Tenoretic Mite)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chlorthalidone alone
Number of subjects: 37
Study: 31262768

Group type: COMPARATOR
Intervention: Single oral doses of TBPM-PI-HBr at 100 mg to 900 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Multiple doses of TBPM-PI-HBr at 300 mg or 600 mg every 8 hours
Number of subjects: 124

Group type: COMPARATOR
Intervention: Multiple doses of TBPM-PI-HBr at 600 mg q8h
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Number of subjects: 124
Study: 29847330

Group type: EXPERIMENTAL
Intervention: Unconditional cash grant
Number of subjects: 2170

Group type: COMPARATOR
Intervention: Mental planning
Number of subjects: 2170
Study: 26948785

Group type: EXPERIMENTAL
Intervention: Computer-animated video group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard-only group
Number of subjects: 123
Study: 25135728

Group type: EXPERIMENTAL
Intervention: Selective esophagogastric devascularization (sEGDV)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-selective esophagogastric devascularization (n-sEGDV)
Number of subjects: 180
Study: 21942926

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 21 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-invasive interactive neurostimulation (InterX(®)) for 21 min
Number of subjects: 20
Study: 20724402

Group type: EXPERIMENTAL
Intervention: Quetiapine (400 mg/day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 178
Study: 17650270

Group type: EXPERIMENTAL
Intervention: Systemic group psychotherapy (S)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Analytic group psychotherapy (A)
Number of subjects: 151
Study: 16234046

Group type: EXPERIMENTAL
Intervention: Atropine (.02 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythromycin (1 or 3 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 40
Study: 12148111

Group type: EXPERIMENTAL
Intervention: Ultrabag (UB)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Stay-Safe (SS)
Number of subjects: 110
Study: 10425980

Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine (30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 8529087

Group type: EXPERIMENTAL
Intervention: Low-fat diet and intensive physical exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 2075382

Group type: EXPERIMENTAL
Intervention: Mebendazole-citrate (500 mg) given daily for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mebendazole-citrate (500 mg) given twice daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levamisole 150 mg (two priming doses)
Number of subjects: 20
Study: 6753559

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone (200 mg 4 times daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 31534549

Group type: EXPERIMENTAL
Intervention: COX-2 specific inhibitor Rofecoxib
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined COX-2 and DNMT inhibition using Celecoxib and Decitabine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 42
Study: 29105115

Group type: EXPERIMENTAL
Intervention: Taurine (6 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 27348000

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg∙kg(‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 11
Study: 24163058

Group type: EXPERIMENTAL
Intervention: Nerve block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study: 22262013

Group type: EXPERIMENTAL
Intervention: Typing and mousing tasks for 60 min at a standardized workstation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no trapezius myalgia)
Number of subjects: 20
Study: 19278329

Group type: EXPERIMENTAL
Intervention: Noninvasive laser-guided preincision localization device
Number of subjects: 76

Group type: COMPARATOR
Intervention: Surgeon's initial estimate of the target site
Number of subjects: 76